Perampanel ameliorates nitroglycerin-induced migraine through inhibition of the cAMP/ PKA/CREB signaling pathway in the trigeminal ganglion in rats
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Perampanel, a highly selective glutamate AMPA receptor antagonist, is widely used to treat epilepsy. Since the existence of common pathophysiological features between epilepsy and migraine, the aim of this study was to investigate whether perampanel could exert an antimigraine effect. Methods: Nitroglycerin (NTG) was used to induce a migraine model in rats, and the model animals were pretreatment with 50 μg/kg and 100 μg/kg perampanel. The expression of pituitary adenylate-cyclase-activating polypeptide (PACAP) was quantified by western blot and quantitative real-time PCR in the trigeminal ganglion, and rat-specific enzyme-linked immunosorbent assay in serum. Western blot was also conducted to explore the effects of perampanel treatment on the phospholipase C (PLC)/protein kinase C (PKC) and protein kinase A (PKA)/ cAMP-responsive-element-binding protein (CREB) signaling pathways. Moreover, the cAMP/PKA/CREB-dependent mechanism was evaluated via in vitro stimulation of hippocampal neurons. The cells were treated with perampanel, antagonists and agonists for 24 hours and cell lysates were prepared for western blot analysis. Results: Perampanel treatment notably increased the mechanical withdrawal threshold and decreased head grooming and light-aversive behaviors in NTG-treated rats. It also decreased PACAP expression and affected cAMP/ PKA/CREB signaling pathway. However, PLC/PKC signaling pathway may not be involved in this treatment. In in vitro studies, perampanel notably decreased PACAP expression by inhibiting cAMP/PKA/CREB signaling pathway. Conclusions: This study shows that perampanel inhibits the migraine-like pain response and that this beneficial effect might be attributable to regulation of the cAMP/PKA/CREB signaling pathway.
Abstract
Background: Perampanel, a highly selective glutamate AMPA receptor antagonist, is widely used to treat epilepsy. Since the existence of common pathophysiological features between epilepsy and migraine, the aim of this study was to investigate whether perampanel could exert an antimigraine effect. Methods: Nitroglycerin (NTG) was used to induce a migraine model in rats, and the model animals were pretreatment with 50 μg/kg and 100 μg/kg perampanel. The expression of pituitary adenylate-cyclase-activating polypeptide (PACAP) was quantified by western blot and quantitative real-time PCR in the trigeminal ganglion, and rat-specific enzyme-linked immunosorbent assay in serum. Western blot was also conducted to explore the effects of perampanel treatment on the phospholipase C (PLC)/protein kinase C (PKC) and protein kinase A (PKA)/ cAMP-responsive-element-binding protein (CREB) signaling pathways. Moreover, the cAMP/PKA/CREB-dependent mechanism was evaluated via in vitro stimulation of hippocampal neurons. The cells were treated with perampanel, antagonists and agonists for 24 hours and cell lysates were prepared for western blot analysis. Results: Perampanel treatment notably increased the mechanical withdrawal threshold and decreased head grooming and light-aversive behaviors in NTG-treated rats. It also decreased PACAP expression and affected cAMP/ PKA/CREB signaling pathway. However, PLC/PKC signaling pathway may not be involved in this treatment. In in vitro studies, perampanel notably decreased PACAP expression by inhibiting cAMP/PKA/CREB signaling pathway. Conclusions: This study shows that perampanel inhibits the migraine-like pain response and that this beneficial effect might be attributable to regulation of the cAMP/PKA/CREB signaling pathway.
참고문헌 (33)
- Global Burden of Disease Study 2013 Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013", Lancet, 386, pp.743~800 (2015)
- GBD 2015 Neurological Disorders Collaborator Group, "Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015", Lancet Neurol, 16, pp.877~897 (2017)
- "Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition", Cephalalgia, 1~211 (2018)
- Pradhan AA, "Characterization of a novel model of chronic migraine", Pain, 155, pp.269~274 (2014)
- Tuka B, "Release of PACAP-38 in episodic cluster headache patients-an exploratory study", J Headache Pain, 17, pp.69~ (2016)
- Amin FM, "Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38", Brain, 137, pp.779~794 (2014)
- Markovics A, "Pituitary adenylate cyclaseactivating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice", Neurobiol Dis, 45, pp.633~644 (2012)
- Hanada T, "Perampanel : a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy", Epilepsia, 52, pp.1331~1340 (2011)
- Roche KW, "Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit", Neuron, 16, pp.1179~1188 (1996)
- Nye BL, "Migraine and epilepsy : review of the literature", Headache, 55, pp.359~380 (2015)
- Chan K, "Glutamate receptor antagonists in the management of migraine", Drugs, 74, pp.1165~1176 (2014)
- Park JS, "Role of spinal cord alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors in complete Freund's adjuvant-induced inflammatory pain", Mol Pain, 4, pp.67~ (2008)
- Tringali G, "Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro", J Headache Pain, 19, pp.107~ (2018)
- Villalón CM, "The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs", Pharmacol Ther, 124, pp.309~323 (2009)
- Hara K, "Intrathecally administered perampanel alleviates neuropathic and inflammatory pain in rats", Eur J Pharmacol, 872, pp.172949~ (2020)
- Askari-Zahabi K, "Orexin one receptors within the basolateral amygdala are involved in the modulation of cognitive deficits associated with a migrainelike state in rats", Neurol Res, 43, pp.1087~1097 (2021)
- Mahmoudi J, "Cerebrolysin attenuates hyperalgesia, photophobia, and neuroinflammation in a nitroglycerin-induced migraine model in rats", Brain Res Bull, 140, pp.197~204 (2018)
- Tang Y, "AMPA receptor GluA1 Ser831 phosphorylation is critical for nitroglycerin-induced migraine-like pain", Neuropharmacology, 133, pp.462~469 (2018)
- Mustelin L, "Association between eating disorders and migraine may be explained by major depression", Int J Eat Disord, 47, pp.884~887 (2014)
- Wang K, "Cryptotanshinone ameliorates CUS-induced depressive-like behaviors in mice", Transl Neurosci, 12, pp.469~481 (2021)
- Liu L, "The neuroprotective and antidepressant-like effects of Hcyb1, a novel selective PDE2 inhibitor", CNS Neurosci Ther, 24, pp.652~660 (2018)
- Carruthers AM, "Adenosine A(1)receptormediated inhibition of protein kinase A-induced calcitonin gene-related peptide release from rat trigeminal neurons", Mol Pharmacol, 59, pp.1533~1541 (2001)
- Alireza Baratloo, "Intravenous caffeine citrate vs. magnesium sulfate for reducing pain in patients with acute migraine headache; a prospective quasi-experimental study", The Korean Journal of Pain, 30(3), pp.176~182 (2017), 대한통증학회
- Casili G, "Dimethyl fumarate alleviates the nitroglycerin(NTG)-induced migraine in mice", J Neuroinflammation, 17, pp.59~ (2020)
- Deen M, "Blocking CGRP in migraine patients - a review of pros and cons", J Headache Pain, 18, pp.96~ (2017)
- Goadsby PJ, "Migraine--current understanding and treatment", N Engl J Med, 346, pp.257~270 (2002)
- Han X, "Chronic changes in pituitary adenylate cyclase-activating polypeptide and related receptors in response to repeated chemical dural stimulation in rats", Mol Pain, 13 (2017)
- Brewerton TD, "Is migraine related to the eating disorders?", Int J Eat Disord, 14, pp.75~79 (1993)
- D'Andrea G, "Is migraine a risk factor for the occurrence of eating disorders? Prevalence and biochemical evidences", Neurol Sci, 33(Suppl 1), pp.S71~S76 (2012)
- Catterall WA, "Regulation of cardiac calcium channels in the fight-or-flight response", Curr Mol Pharmacol, 8, pp.12~21 (2015)
- Ahuja M, "cAMP and Ca²+ signaling in secretory epithelia : crosstalk and synergism", Cell Calcium, 55, pp.385~393 (2014)
- Chen T, "Postsynaptic potentiation of corticospinal projecting neurons in the anterior cingulate cortex after nerve injury", Mol Pain, 10, pp.33~ (2014)
- Yue X, "Sustained morphine treatment augments basal CGRP release from cultured primary sensory neurons in a Raf-1 dependent manner", Eur J Pharmacol, 584, pp.272~277 (2008)